Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mPEG112-b-PBLG5 (HIP)
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
mPEG112-b-PBLG5 (HIP) is an experimental nanotherapeutic consisting of a HuR-inhibiting peptide (HIP) formulated with a methoxy poly(ethylene glycol)-block-poly(gamma-benzyl-L-glutamate) (mPEG-b-PBLG) block copolymer. The drug is designed to target Human Antigen R (HuR), also known as ELAV-like protein 1, which is an RNA-binding protein that stabilizes the mRNA of pro-inflammatory cytokines. By inhibiting the structural interaction between HuR and its target RNAs, the HIP peptide prevents the downstream expression of inflammatory mediators. The mPEG112-b-PBLG5 copolymer serves as a delivery vehicle, forming polymeric micelles that enhance the stability and targeted delivery of the peptide. This therapeutic strategy is being investigated for the treatment of immune-mediated inflammatory diseases, specifically psoriasis, where it has demonstrated efficacy in reducing skin inflammation in preclinical mouse models.
- Other names
- HuR-inhibiting peptide nanoparticlePEGylated HuR-inhibiting peptidemPEG112-b-PBLG5-HIPmPEG-112-b-PBLG5-HIPmPEG 112-b-PBLG5-HIP
02
Targets
ELAVL1 (Human Antigen R)
Beyond the preview
Go deeper on mPEG112-b-PBLG5 (HIP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mPEG112-b-PBLG5 (HIP).